SARS-CoV-2 Versus Influenza-associated Acute Respiratory Distress Syndrome Requiring Veno-venous Extracorporeal Membrane Oxygenation Support
view event
Pulsatile perfusion: What are the benefits, and do they outweigh the risks? Physiologic pulse pressure and circuit limitations will be discussed | Perfusion Education
view event
Vanderbilt University Medical Center; Department of CV Surgery: Faculty Forum:
John Ingram is a magna cum laude graduate from University of Texas, Texas Heart Institute and a board certified perfusionist currently specializing in adult perfusion as well as pediatric and adult ECMO. He has several medical patents and has served as a consultant for nearly every perfusion manufacturer. He has published seven research publications in the perfusion literature, and has presented both nationally and internationally. With fifteen years experience as a Chief Perfusionist, and thirty years perfusion experience in total, he presently provides nationwide temporary and long term locum tenens coverage.
Tammy graduated from Texas Heart Institute and had been practicing for nearly 17 years in the Houston and surrounding areas. She is employed with Houston Extracorporeal Technologies as a clinical perfusionist. Her professional interests are perfusion education, ECMO management and blood conservation.
Dr. Hoffman was born in New Orleans, Louisiana and was raised in Los Angeles, California. His undergraduate degree is from Rice University in Houston, Texas. He attended medical school at Tulane University in New Orleans, Louisiana and simultaneously received his MPH from the Tulane School of Public Health and Tropical Medicine. Dr. Hoffman’s general surgical training began at Emory and Grady Hospitals in Atlanta, Georgia followed by a fellowship in Cardiothoracic Surgery at University of Colorado in Denver, Colorado.
Dr. Hoffman's clinical interests include end-stage heart and lung disease, pulmonary hypertension, mechanical support and devices, as well as aortic surgery. His research interests involve studying heart failure physiology in patient’s undergoing LVAD placement and novel therapies to extend the viability of donor hearts.
